Novacyt S.A.
("Novacyt", the "Company" or the
"Group")
Directorate Change
Dr Ian Gilham appointed as Non-Executive
Director
Paris, France, Eastleigh and
Manchester, UK - 31 October 2024 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international molecular diagnostics
company with a broad portfolio of integrated technologies and
services,
announces the appointment of Dr Ian Gilham as a Non-Executive
Director with immediate effect. Dr Gilham will become a Board Director of
the Company, subject to shareholder approval, at the Company's
Annual General Meeting.
Ian has a wealth of experience in
AIM-listed life sciences companies, with an international track
record in the research, development and commercialisation of
diagnostic products that will further strengthen the expertise of
the Novacyt Board. He currently holds roles as Non-Executive
Chairman of AIM-listed Genedrive PLC, Chair of Trustees for
LifeArc, a self-funded medical research charity, Non-Executive
Chairman of Pelago Bioscience AB, a life sciences tools business
based in Stockholm and Non-Executive Chairman of RevoNA Bio, a
University of Portsmouth spinout life sciences tools company. Ian
has previously held Board positions at Aptamer Group PLC, Horizon
Discovery PLC, Cytox Ltd, Elucigene Ltd, Multiplicom n.v, Biosufit
s.a, Vernalis plc, Concepta Diagnostics Ltd and was CEO of
Axis-Shield PLC.
Dr Ian Gilham, Non-Executive
Director of Novacyt S.A.
Lyn Rees, CEO of Novacyt,
commented: "It is a pleasure to welcome Ian to the
Board of Novacyt. Ian has worked with a number of successful
AIM-listed life sciences companies and we look forward to utilising
his expertise as we further optimise and strengthen the Novacyt
Group."
Additional
Information
The
following information is disclosed pursuant to Rule 17 and Schedule
Two paragraph (g) of the AIM Rules for Companies in relation to Ian
David Gilham aged 64.
|
Current Directorships /
Partnerships
|
Former Directorships / Partnerships
within the last 5 years
|
|
Genedrive Plc
LifeArc
Pelago
Bioscience AB
Revona
Bio Ltd
Stowheath Limited
|
Aptamer
Group Plc
BIOSURFIT s.a
Cytox
Limited
Horizon
Discovery Group Limited (Formerly Horizon Discovery Plc)
Revvity
Discovery Limited (Formerly Horizon Discovery Limited)
|
On 4
January 2024, Cytox Limited, a company which Ian Gilham was
previously a director of, appointed a liquidator in connection with
a creditors voluntary winding up. No notice of
administrators' proposal has yet been filed although the business
was estimated to have a deficiency as regards creditors of
£257,405.
Save as disclosed above, there is no
further information to be disclosed in respect of the above
appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the
AIM Rules for Companies.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR (Financial PR &
IR)
Paul
McManus / Lianne Applegarth
Phillip
Marriage / Alice Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7980 541 893 / +44 (0)7584 391 303
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
·
genesig q16 and q32 real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
·
Pharmaceutical research services: whole genome
sequencing (WGS) / whole exome sequencing (WES)
|
Novacyt is headquartered in
Vélizy-Villacoublay in France with offices in the UK (in Eastleigh
and Manchester), Singapore, the US and Canada and has a commercial
presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock
Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com